Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of re-irradiation plus Erbitux for unresectable locally recurrent head and neck squamous cell carcinoma
2009-015457-21Phase 2Completed
- Sponsor
- GORTEC
- Start
- Nov 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Primary endpoint: Complete response rate. Started Nov 2009; status: completed.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2009-015457-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015457-21.